Your browser doesn't support javascript.
loading
Early-like differentiation status of systemic PD-1+CD8+ T cells predicts PD-1 blockade outcome in non-small cell lung cancer.
Khanniche, Asma; Yang, Yi; Zhang, Jie; Liu, Shiqing; Xia, Liliang; Duan, Huangqi; Yao, Yaxian; Zhao, Bingrong; Zhao, Guo-Ping; Hu, Chengping; Wang, Ying; Lu, Shun.
Afiliación
  • Khanniche A; Department of Immunology and Microbiology, Shanghai Institute of Immunology Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Yang Y; Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen China.
  • Zhang J; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China.
  • Liu S; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China.
  • Xia L; Department of Respiratory Medicine, Xiangya Lung Cancer Center, Xiangya Hospital Central South University Changsha China.
  • Duan H; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China.
  • Yao Y; Department of Immunology and Microbiology, Shanghai Institute of Immunology Shanghai Jiao Tong University School of Medicine Shanghai China.
  • Zhao B; Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China.
  • Zhao GP; Department of Respiratory Medicine, Xiangya Lung Cancer Center, Xiangya Hospital Central South University Changsha China.
  • Hu C; Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences Shenzhen China.
  • Wang Y; Department of Respiratory Medicine, Xiangya Lung Cancer Center, Xiangya Hospital Central South University Changsha China.
  • Lu S; Department of Immunology and Microbiology, Shanghai Institute of Immunology Shanghai Jiao Tong University School of Medicine Shanghai China.
Clin Transl Immunology ; 11(7): e1406, 2022.
Article en En | MEDLINE | ID: mdl-35910005
Objectives: Despite remarkable advances in the treatment of non-small cell lung cancer (NSCLC) with anti-programmed death (PD)-1 therapy; only a fraction of patients derives durable clinical benefit. In this study, we investigated whether the differentiation status of systemic CD8+ T cells predicts the outcome of PD-1 blockade in NSCLC. Methods: We carried out a prospective study on a total of 77 NSCLC patients receiving anti-PD-1 blockers, among which 47 patients were assigned as a discovery cohort and 30 patients as a validation cohort. Peripheral blood samples were obtained at baseline and upon multiple therapy cycles and analyzed by multi-parameter flow cytometry. Results: We found that a higher baseline ratio of PD-1+ early effector memory CD8+ T cells (CD28+CD27-CD45RO+, TEEM) to PD-1+ effector CD8+ T cells (CD28-CD27-CD45RO-, TE) delineated responders to PD-1 blockade from progressors and was associated with prolonged progression-free survival (PFS) and durable clinical benefit. Moreover, PD-1+CD8 TEEM cells exhibited early responses after anti-PD-1 therapy and was the major fraction of cycling PD-1+Ki67+CD8+ T cells to expand specifically with positive impact on PFS. Conclusion: These findings provide insights into how the baseline differentiation status of the peripheral immune system determines responses to PD-1-targeted therapies.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Transl Immunology Año: 2022 Tipo del documento: Article Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Transl Immunology Año: 2022 Tipo del documento: Article Pais de publicación: Australia